Posts

The Other Patient: Care for the Caregivers

Image
Informed Prostate Cancer Support Group (IPCSG) Newsletter  |  April 2026 What Our Partners and Caregivers Carry on This Roller Coaster A close look at the hidden burden borne by spouses and care partners across surgery, ADT, radiation, imaging, and theranostics   Prepared for the IPCSG Community  |  April 2026 Bottom Line Up Front (BLUF) When a man is diagnosed with prostate cancer and embarks on treatment — whether surgery, radiation, androgen deprivation therapy (ADT), PSMA imaging, or the newest theranostics — his spouse or care partner shoulders a second, often invisible, patient journey alongside him. Research consistently shows that partners experience rates of anxiety and depression equal to or greater than patients, sacrifice thousands of hours of work and personal time, suffer significant sexual and intimacy losses, and receive far less clinical attention th...
Post a Comment
Read more

Genetic Testing for Prostate Cancer:

Image
  What tools do men need to make an informed decision about germline genetic testing for prostate cancer: A qualitative and survey study | medRxiv What Every Patient Should Know in 2026 A new wave of guidelines, approved therapies, and patient-centered tools is making germline genetic testing a standard part of prostate cancer care — but most men still haven't been tested. Here's what you need to know. Bottom Line Up Front (BLUF) Germline genetic testing — a blood or saliva test that looks for inherited gene changes — has become a cornerstone of prostate cancer care in 2025–2026. Both ASCO and NCCN now recommend it broadly for men with metastatic, high-risk, or locally advanced disease, and for men with relevant family histories. Knowing your genetic status can guide which treatments will work best for you (including PARP inhibitors like olaparib and rucaparib), alert your sons, brothers, and other relatives to start screening earlier, and reve...
Post a Comment
Read more

When Your Cancer Drug Affects Your Heart:

Image
Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone | Cardio-Oncology | Springer Nature Link What Every Patient on Xtandi or Zytiga Needs to Know A growing mountain of real-world evidence — now spanning six continents and more than 50,000 patients — reveals important differences in cardiovascular risk between two of prostate cancer's most widely used treatments. Bottom Line Up Front (BLUF) What You Need to Know Before Reading Further Both enzalutamide (Xtandi) and abiraterone (Zytiga/Yonsa) are effective and lifesaving treatments for advanced prostate cancer — neither should be stopped without a doctor's guidance. A landmark 2026 Medicare study of nearly 6,000 patients found that abiraterone carries a 12% higher overall risk of serious cardiac events (MACE) than enzalutamide, rising to 16% higher risk among patients with pre-existing heart disease. Abiraterone was associated with 73% gr...
Post a Comment
Read more

Your AI Co-Pilot After Diagnosis:

Image
Using AI to Understand Your Cancer Diagnosis Informed Prostate Cancer Support Group Newsletter — Spring 2026  |  San Diego, California Empowering patients through knowledge since 1999 Patient Education  ·  Digital Health Technology  ·  AI & Cancer Care How Artificial Intelligence Is Changing the Way Prostate Cancer Patients Learn, Prepare, and Engage A prostate cancer diagnosis lands you in an avalanche of unfamiliar language — Gleason grades, TNM staging, PSA kinetics, PSMA PET scans. AI-powered chatbots can now serve as an on-demand interpreter, helping you decode your pathology report, organize your questions, and walk into your doctor's office ready to have a genuinely informed conversation. IPCSG Newsletter Staff  |  Based on the IPCSG Cancer Patient Lab Demonstration Session and Current Peer-Reviewed Research  |  March 2026 Bottom Line Up Front (BLUF): AI chatbo...
Post a Comment
Read more